Completed PHASE2 INTERVENTIONAL 2-arm NCT00645593

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

Phase II Randomized Trial of Gemcitabine and Cisplatin With or Without Cetuximab in Patients With Urothelial Carcinoma

Sponsor: Bristol-Myers Squibb

Interventions Cetuximab Cisplatin Gemcitabine,

Updated 8 times since 2017 Last updated: Apr 14, 2016 Started: Mar 31, 2008 Primary completion: Apr 30, 2014 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00645593, this PHASE2 trial focuses on Bladder Cancer and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 8 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2
Feb 2019 — Nov 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Feb 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Eli Lilly and Company
National Comprehensive Cancer Network
University of Michigan Rogel Cancer Center

Data source: University of Michigan Rogel Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Boston, United States , Buffalo, United States , Burlington, United States , Chicago, United States , Detroit, United States , Duarte, United States , Houston, United States , Los Angeles, United States and 4 more locations